Acadia delivered a second quarter where both commercial franchises printed in lockstep with the bull thesis: NUPLAZID, the only FDA-approved therapy for Parkinson's disease psychosis, generated GAAP net sales of $183.2 million, up 9% year-over-year on a GAAP basis and 10% on a non-GAAP adjusted basis, while DAYBUE, the only FDA-approved treatment for Rett syndrome, generated $124.8 million, up 30% year-over-year, with the new DAYBUE STIX powder formulation driving most of that acceleration. Total revenue of $308.0 million was up 16% on a GAAP basis, and management used the quarter to raise full-year 2026 total revenue guidance to $1.24-$1.30 billion from a prior $1.22-$1.28 billion, with DAYBUE guided to $480-$510 million (up from $460-$490 million) and NUPLAZID reaffirmed at $760-$790 million. The load-bearing observation is what management did with the cash: net cash from operations of $134.8 million in the first half, a 60% step-up from $84.3 million a year ago, took the balance sheet to $956.5 million in cash and investments at quarter-end, comfortably ahead of the cash burn profile of a company that ran an accumulated deficit of approximately $1.8 billion as of mid-2026.
The single load-bearing risk is the Phase 2 RADIANT topline for remlifanserin in Alzheimer's disease psychosis, expected September to October 2026. This is the readout that determines whether the third leg of the franchise exists. A miss in a Phase 2 trial of an antipsychotic in a notoriously heterogeneous Alzheimer's population is the binary event that would re-rate the equity; a clear win, particularly with the FDA Fast Track designation granted in July 2026, opens the door to a label that addresses a population with no approved therapy. The market is pricing a roughly 14% upside to consensus targets on the existing two-product base alone, before any credit for remlifanserin. In our view, the next six months are about the readout, and the question the quarter answers for the equity is whether Acadia can compound two cash-generative rare-disease assets while a third, much larger, opportunity matures behind them.